Sharma S, Oliver-Fernandez A, Bakal J, Hollands H, Brown G C, Brown M M
The Cost-Effective Ocular Health Policy Unit, Queen's University, Hotel Dieu Hospital, Kingston, ON, Canada.
Br J Ophthalmol. 2003 Mar;87(3):259-61. doi: 10.1136/bjo.87.3.259.
BACKGROUND/AIMS: To report patient based utilities, using the time trade-off technique, associated with visual loss secondary to diabetic retinopathy in a sample of Canadian patients. In addition, to compare these utility values with a sample collected in a similar manner in a tertiary care practice in the United States.
A cross sectional study of eligible patients with diabetic retinopathy presenting to a tertiary facility was performed. Demographic and clinical variables (including Snellen visual acuity), and utilities were collected both through chart review and standardised interviews with diabetic patients.
221 patients with diabetic retinopathy were eligible for this study and completed the interview. The mean age was 63.5 (SD 12.5) years, and 48.4% were female. Over 35% of the sample had visual acuity in the affected eye of 6/60 or worse. The mean utility for the sample was 0.79 (SD 0.23). The mean utility from this sample did not differ significantly from that obtained from a series of patients with diabetic retinopathy who were referred to a tertiary facility in the United States (mean 0.77, SD 0.21, p=0.313). Our cross border comparison had a power of 95% to detect a difference in utility of 0.1 between the two groups.
On average, Canadian patients with diabetic retinopathy were willing to trade off over 20% of their remaining lifespan in order to eliminate their ocular disease. The mean utility obtained from our sample of Canadian patients with diabetic retinopathy was not statistically different from that obtained from a similar sample of American patients.
背景/目的:采用时间权衡技术报告加拿大患者样本中与糖尿病性视网膜病变继发视力丧失相关的基于患者的效用值。此外,将这些效用值与在美国一家三级医疗中心以类似方式收集的样本进行比较。
对就诊于三级医疗机构的符合条件的糖尿病性视网膜病变患者进行横断面研究。通过病历审查和对糖尿病患者的标准化访谈收集人口统计学和临床变量(包括斯内伦视力)及效用值。
221例糖尿病性视网膜病变患者符合本研究条件并完成访谈。平均年龄为63.5(标准差12.5)岁,48.4%为女性。超过35%的样本患眼视力为6/60或更差。样本的平均效用值为0.79(标准差0.23)。该样本的平均效用值与从美国一家三级医疗机构转诊的一系列糖尿病性视网膜病变患者获得的平均效用值(0.77,标准差0.21,p = 0.313)无显著差异。我们的跨境比较有95%的把握检测出两组效用值相差0.1。
平均而言,加拿大糖尿病性视网膜病变患者愿意牺牲超过20%的剩余寿命以消除眼部疾病。我们加拿大糖尿病性视网膜病变患者样本获得的平均效用值与美国类似患者样本获得的平均效用值无统计学差异。